Sean Kelleher

Elucid Bioimaging is a medical technology company based in the United States that aims to understand and treat the underlying cause of heart attacks and strokes, specifically subclinical atherosclerosis. The company is based in Boston, MA and was founded in 2009 by Andrew Buckler. The company uses AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Elucid Bioimaging's proprietary software, Vascucap, is the first tool to quantify atherosclerotic plaque against histology, deliver key arterial measures, and provide 3D visualization to inform the risk of events such as stroke or heart attack. Vascucap's unique information informs better treatment decisions by physicians, leading to better patient outcomes at a reduced cost of care. The CEO is Blake Richards.

Elucid Bioimaging is a medical technology company based in the United States that aims to understand and treat the underlying cause of heart attacks and strokes, specifically subclinical atherosclerosis. The company is based in Boston, MA and was founded in 2009 by Andrew Buckler. The company uses AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Elucid Bioimaging's proprietary software, Vascucap, is the first tool to quantify atherosclerotic plaque against histology, deliver key arterial measures, and provide 3D visualization to inform the risk of events such as stroke or heart attack. Vascucap's unique information informs better treatment decisions by physicians, leading to better patient outcomes at a reduced cost of care. The CEO is Blake Richards.

Elucid Bioimaging is a medical technology company based in the United States that aims to understand and treat the underlying cause of heart attacks and strokes, specifically subclinical atherosclerosis. The company is based in Boston, MA and was founded in 2009 by Andrew Buckler. The company uses AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Elucid Bioimaging's proprietary software, Vascucap, is the first tool to quantify atherosclerotic plaque against histology, deliver key arterial measures, and provide 3D visualization to inform the risk of events such as stroke or heart attack. Vascucap's unique information informs better treatment decisions by physicians, leading to better patient outcomes at a reduced cost of care. The CEO is Blake Richards.

Elucid Bioimaging is a medical technology company based in the United States that aims to understand and treat the underlying cause of heart attacks and strokes, specifically subclinical atherosclerosis. The company is based in Boston, MA and was founded in 2009 by Andrew Buckler. The company uses AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Elucid Bioimaging's proprietary software, Vascucap, is the first tool to quantify atherosclerotic plaque against histology, deliver key arterial measures, and provide 3D visualization to inform the risk of events such as stroke or heart attack. Vascucap's unique information informs better treatment decisions by physicians, leading to better patient outcomes at a reduced cost of care. The CEO is Blake Richards.

Elucid Bioimaging is a medical technology company based in the United States that aims to understand and treat the underlying cause of heart attacks and strokes, specifically subclinical atherosclerosis. The company is based in Boston, MA and was founded in 2009 by Andrew Buckler. The company uses AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Elucid Bioimaging's proprietary software, Vascucap, is the first tool to quantify atherosclerotic plaque against histology, deliver key arterial measures, and provide 3D visualization to inform the risk of events such as stroke or heart attack. Vascucap's unique information informs better treatment decisions by physicians, leading to better patient outcomes at a reduced cost of care. The CEO is Blake Richards.